Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5937404 | 0.82 | KDM4E (0.43) | TRPA1MAPK1 | |
| SCHEMBL5937211 | 0.80 | RAB9A (0.49) | TRPA1NOTUMMAPK1SLC22A12SCN5A | |
| SCHEMBL14705879 | 0.77 | HAO1 (0.47) | TRPA1NOTUMSLC22A12 | |
| SCHEMBL23294300 | 0.75 | HAO1 (0.46) | TRPA1NOTUMMMP2MAP4K4 | |
| SCHEMBL7402930 | 0.71 | MEN1 (0.53) | — | |
| SCHEMBL5937229 | 0.69 | ALDH1A1 (0.53) | TRPA1RAB9A | |
| SCHEMBL25143437 | 0.69 | MMP3 (0.41) | TRPA1MAPK1MMP2GSK3BRAB9A | |
| SCHEMBL11070857 | 0.69 | RXFP1 (0.46) | MAPK1RAB9A | |
| SCHEMBL14705961 | 0.66 | KDM4E (0.40) | NOTUMMMP2SLC22A12MAP4K4MAPK13 | |
| SCHEMBL4678365 | 0.66 | MAP2K4 (0.48) | NOTUMMAPK1GSK3BRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052384-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression for the treatment of hypercholesterolemia | GLAXO GROUP LIMITED (GB) | 2006-03-09 | — | — | US | disclosed |
| EP-1539158-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | GLAXO GROUP LIMITED (GB) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004006922-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | GLAXO GROUP LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052384-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression for the treatment of hypercholesterolemia | LDLR, NR1H2, NR1H3 | TRPA1 596/4885NOTUM 1312/4885MAPK1 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.